Obstructive Hypertrophic Cardiomyopathy Clinical Trial
Official title:
Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
NCT number | NCT05726799 |
Other study ID # | CRYO-MOR |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 5, 2019 |
Est. completion date | October 15, 2019 |
Verified date | February 2023 |
Source | Ospedale San Raffaele |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In some patients, septal hypertrophy extends more distally, from the subaortic portion of the septum to the midventricular portion. In these patients, classic transaortic surgical myectomy may not be effective in removing the midventricular obstruction, resulting in a suboptimal surgical outcome. These patients may present recurrence of symptoms and not have an improvement in the prognosis related to the treatment of hypertrophic cardiomyopathy, in some cases determining the need for reoperation. Since 2015, our Institute has used a surgical technique that allows us to improve transaortic exposure of the interventricular septum, using a probe with application of cryoenergy the hypertrophic portion of the septum is hooked and in this way the myectomy can be extended more distally, performing a more complete removal of the myocardium. The aim of this study is to compare the results obtained with classical myectomy compared to myectomy performed with the aid of cryoenergy. The primary endpoint is the comparison in terms of mortality between patients undergoing classical myectomy versus those undergoing cryoenergy-assisted myectomy. Secondary endpoints are: extent of myectomy, persistence of residual left ventricular outflow tract obstruction, persistence of mitral regurgitation related to systolic anterior motion of the mitral leaflets, occurrence of ventricular defect, and need for PM implantation.
Status | Completed |
Enrollment | 60 |
Est. completion date | October 15, 2019 |
Est. primary completion date | October 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - adult patients (= 18 years) - meeting the clinical and echocardiographic criteria that made them candidates for isolated myectomy or in combination with other surgical procedures: - LV outflow tract instantaneous peak gradient >50mmHg at rest or during stimulation - interventricular septum >16mm, - NYHA functional class III-IV, despite maximal medical therapy - operated in San Raffaele Hospital with classic or cryo myectomy between 2015 and 2018. Exclusion Criteria: - extent of myectomy not reported in the operative report; - left ventricular outflow tract gradient not reported in pre- or postoperative echocardiography. |
Country | Name | City | State |
---|---|---|---|
Italy | IRCCS Ospedale San Raffaele | Milan |
Lead Sponsor | Collaborator |
---|---|
Michele De Bonis |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality | Up to 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06023186 -
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
|
||
Active, not recruiting |
NCT03723655 -
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
|
Phase 2/Phase 3 | |
Completed |
NCT04603521 -
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
|
||
Active, not recruiting |
NCT06211595 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
Recruiting |
NCT06116968 -
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
|
Phase 3 | |
Completed |
NCT03470545 -
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
Phase 3 | |
Recruiting |
NCT05879523 -
A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy
|
Phase 1 | |
Not yet recruiting |
NCT06146660 -
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT05771987 -
Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
|
N/A | |
Active, not recruiting |
NCT05174416 -
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
|
Phase 3 | |
Recruiting |
NCT06224621 -
Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy
|
N/A | |
Completed |
NCT01631006 -
Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT06368037 -
Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
Recruiting |
NCT05489705 -
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
|
||
Completed |
NCT06354556 -
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04783766 -
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
|
Phase 1 |